ArticleFrontiers in medicine2025

Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases.

Kaidi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.